These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1170 related articles for article (PubMed ID: 31111345)

  • 1. Changes in APRI and FIB-4 in HBeAg-negative treatment-naive chronic hepatitis B patients with significant liver histological lesions receiving 5-year entecavir therapy.
    Liu R; Guo J; Lu Y; Zhang L; Shen G; Wu S; Chang M; Hu L; Hao H; Li M; Xie Y
    Clin Exp Med; 2019 Aug; 19(3):309-320. PubMed ID: 31111345
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship between virological response and FIB-4 index in chronic hepatitis B patients with entecavir therapy.
    Li N; Xu JH; Yu M; Wang S; Si CW; Yu YY
    World J Gastroenterol; 2015 Nov; 21(43):12421-9. PubMed ID: 26604649
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes of FibroScan, APRI, and FIB-4 in chronic hepatitis B patients with significant liver histological changes receiving 3-year entecavir therapy.
    Li Q; Chen L; Zhou Y
    Clin Exp Med; 2018 May; 18(2):273-282. PubMed ID: 29350286
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessing significant fibrosis using imaging-based elastography in chronic hepatitis B patients: Pilot study.
    Park HS; Choe WH; Han HS; Yu MH; Kim YJ; Jung SI; Kim JH; Kwon SY
    World J Gastroenterol; 2019 Jul; 25(25):3256-3267. PubMed ID: 31333316
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acoustic Radiation Force Impulse Elastography with APRI and FIB-4 to Identify Significant Liver Fibrosis in Chronic Hepatitis B Patients.
    Tseng CH; Chang CY; Mo LR; Lin JT; Tai CM; Perng DS; Lin CW; Hsu YC
    Ann Hepatol; 2018 Aug; 17(5):789-794. PubMed ID: 30145564
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Value of gamma-glutamyltranspeptidase-to-platelet ratio in diagnosis of hepatic fibrosis in patients with chronic hepatitis B.
    Hu YC; Liu H; Liu XY; Ma LN; Guan YH; Luo X; Ding XC
    World J Gastroenterol; 2017 Nov; 23(41):7425-7432. PubMed ID: 29151696
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Histological outcome for chronic hepatitis B patients treated with entecavir vs lamivudine-based therapy.
    Wang JL; Du XF; Chen SL; Yu YQ; Wang J; Hu XQ; Shao LY; Chen JZ; Weng XH; Zhang WH
    World J Gastroenterol; 2015 Aug; 21(32):9598-606. PubMed ID: 26327767
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of APRI and FIB-4 for noninvasive assessment of significant fibrosis and cirrhosis in HBeAg-negative CHB patients with ALT ≤ 2 ULN: A retrospective cohort study.
    Li Q; Ren X; Lu C; Li W; Huang Y; Chen L
    Medicine (Baltimore); 2017 Mar; 96(12):e6336. PubMed ID: 28328813
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The gamma-glutamyl transpeptidase-to-platelet ratio predicts liver fibrosis and cirrhosis in HBeAg-positive chronic HBV infection patients with high HBV DNA and normal or mildly elevated alanine transaminase levels in China.
    Li Q; Li W; Huang Y; Chen L
    J Viral Hepat; 2016 Nov; 23(11):912-919. PubMed ID: 27375134
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative evaluation of GPR versus APRI and FIB-4 in predicting different levels of liver fibrosis of chronic hepatitis B.
    Liu DP; Lu W; Zhang ZQ; Wang YB; Ding RR; Zhou XL; Huang D; Li XF
    J Viral Hepat; 2018 May; 25(5):581-589. PubMed ID: 29230907
    [TBL] [Abstract][Full Text] [Related]  

  • 11. APRI, the FIB-4 score, and Forn's index have noninvasive diagnostic value for liver fibrosis in patients with chronic hepatitis B.
    Ucar F; Sezer S; Ginis Z; Ozturk G; Albayrak A; Basar O; Ekiz F; Coban S; Yuksel O; Armutcu F; Akbal E
    Eur J Gastroenterol Hepatol; 2013 Sep; 25(9):1076-81. PubMed ID: 23510962
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does regression in treatment-induced liver fibrosis reflect noninvasive tests? Assessing treatment results of hepatitis B patients who took potent antiviral drugs for 5 years.
    Yalaki S; Yalcin MS
    Niger J Clin Pract; 2020 Feb; 23(2):226-231. PubMed ID: 32031098
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stepwise application of fibrosis index based on four factors, red cell distribution width-platelet ratio, and aspartate aminotransferase-platelet ratio for compensated hepatitis B fibrosis detection.
    Chen YP; Hu XM; Liang XE; Huang LW; Zhu YF; Hou JL
    J Gastroenterol Hepatol; 2018 Jan; 33(1):256-263. PubMed ID: 28452125
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of prolonged entecavir monotherapy in treatment-naïve chronic hepatitis B patients exhibiting a partial virologic response to entecavir.
    Choi HN; Song JE; Lee HC; Jo HH; Lee CH; Kim BS
    Clin Mol Hepatol; 2015 Mar; 21(1):24-31. PubMed ID: 25834799
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Easy Liver Fibrosis Test (eLIFT) for predicting advanced liver fibrosis in patients with chronic hepatitis B.
    Wang J; Chen Z; Yan X; Yang Y; Liu Y; Chen Y; Jia B; Xia J; Xiong Y; Zhang Z; Ding W; Huang R; Wu C
    Discov Med; 2019 Sep; 28(153):149-158. PubMed ID: 31926586
    [TBL] [Abstract][Full Text] [Related]  

  • 16. AST/ALT ratio, APRI, and FIB-4 compared to FibroScan for the assessment of liver fibrosis in patients with chronic hepatitis B in Bandar Abbas, Hormozgan, Iran.
    Moosavy SH; Eftekhar E; Davoodian P; Nejatizadeh A; Shadman M; Zare S; Nazarnezhad MA
    BMC Gastroenterol; 2023 May; 23(1):145. PubMed ID: 37170243
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Entecavir and Tenofovir Treatment on Noninvasive Fibrosis Scores: Which One Is Better?
    Koksal AR; Alkim H; Boga S; Ergun M; Bayram M; Ozguven BY; Alkim C
    Am J Ther; 2016; 23(2):e429-38. PubMed ID: 25650531
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of APRI and FIB-4 scoring systems for non-invasive assessment of hepatic fibrosis in chronic hepatitis B patients.
    Kim WR; Berg T; Asselah T; Flisiak R; Fung S; Gordon SC; Janssen HL; Lampertico P; Lau D; Bornstein JD; Schall RE; Dinh P; Yee LJ; Martins EB; Lim SG; Loomba R; Petersen J; Buti M; Marcellin P
    J Hepatol; 2016 Apr; 64(4):773-80. PubMed ID: 26626497
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Predictive value of liver pathologic changes in determining the effectiveness of entecavir treatment for chronic hepatitis B-An analysis of 1 366 cases].
    Sun MM; Zhang W; Chen G; An Y; Wang YQ; Shang QH
    Zhonghua Yi Xue Za Zhi; 2017 Apr; 97(15):1160-1164. PubMed ID: 28427123
    [No Abstract]   [Full Text] [Related]  

  • 20. Long-term effects of entecavir and tenofovir treatment on the fibrotic burden in patients with chronic hepatitis B.
    Chon YE; Kim SU; Seo YS; Lee HW; Lee HA; Kim MN; Roh YH; Park JY; Kim DY; Ahn SH; Tak WY; Park SY; Kim BK
    J Gastroenterol Hepatol; 2022 Jan; 37(1):200-207. PubMed ID: 34478195
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 59.